Success Metrics

Clinical Success Rate
100.0%

Based on 12 completed trials

Completion Rate
100%(12/12)
Active Trials
0(0%)
Results Posted
33%(4 trials)

Phase Distribution

Ph phase_1
3
23%
Ph phase_3
5
38%
Ph phase_4
5
38%

Phase Distribution

3

Early Stage

0

Mid Stage

10

Late Stage

Phase Distribution13 total trials
Phase 1Safety & dosage
3(23.1%)
Phase 3Large-scale testing
5(38.5%)
Phase 4Post-market surveillance
5(38.5%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

100.0%

12 of 12 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

13

all time

Status Distribution
Completed(12)
Other(1)

Detailed Status

Completed12
unknown1

Development Timeline

Analytics

Development Status

Total Trials
13
Active
0
Success Rate
100.0%
Most Advanced
Phase 4

Trials by Phase

Phase 13 (23.1%)
Phase 35 (38.5%)
Phase 45 (38.5%)

Trials by Status

completed1292%
unknown18%

Recent Activity

0 active trials
Showing 5 of 13
completedphase_3

Confirmatory Study of MT-2412 in Japanese Patients With Type 2 Diabetes (Add-on Study of Teneligliptin)

NCT02354222
completedphase_3

Confirmatory Study of MT-2412 in Japanese Patients With Type 2 Diabetes (Add-on Study of Canagliflozin)

NCT02354235
completedphase_3

Long-term Safety Study of MP-513 as Monotherapy or in Combination With Sulfonylurea in Japanese Type 2 Diabetic Patients

NCT02314637
completedphase_3

Long-term Safety Study of MP-513 in Patients With Type 2 Diabetes

NCT01301833
completedphase_1

Pharmacokinetics and Safety of HD-P023 and Co-administration of Teneligliptin and Empagliflozin High in Healthy Volunteers

NCT06889350
View all 13 trials

Clinical Trials (13)

Showing 13 of 13 trials
NCT02354222Phase 3

Confirmatory Study of MT-2412 in Japanese Patients With Type 2 Diabetes (Add-on Study of Teneligliptin)

Completed
NCT02354235Phase 3

Confirmatory Study of MT-2412 in Japanese Patients With Type 2 Diabetes (Add-on Study of Canagliflozin)

Completed
NCT02314637Phase 3

Long-term Safety Study of MP-513 as Monotherapy or in Combination With Sulfonylurea in Japanese Type 2 Diabetic Patients

Completed
NCT01301833Phase 3

Long-term Safety Study of MP-513 in Patients With Type 2 Diabetes

Completed
NCT06889350Phase 1

Pharmacokinetics and Safety of HD-P023 and Co-administration of Teneligliptin and Empagliflozin High in Healthy Volunteers

Completed
NCT06339788Phase 1

Pharmacokinetics of HD-P023 and Co-administration of Teneligliptin and Empagliflozin High in Healthy Volunteers

Completed
NCT02512523Phase 4

Exploratory Study to Compare the Effects of Tenelia® or Januvia® on Glucose Variability in add-on to Metformin (CGMS Study)

Completed
NCT03508323Phase 4

Tenelia Elderly CGMS Study(TEDDY)

Completed
NCT04431141Phase 1

Pharmacokinetic Drug Interaction Between Teneligliptin and Empagliflozin

Completed
NCT04446026Phase 4

A Randomized, Placebo-controlled Clinical Trial of Teneligliptin as Quadruple Oral Combination Therapy for Type 2 DM After Failure of an Oral Triple Anti-diabetic Regimen

Completed
NCT03011177Phase 4

Teneligliptin Versus Linagliptin in Diabetes Mellitus Type Two Patients

Completed
NCT02449330Phase 4

Teneligliptin on the Progressive Left Ventricular Diastolic Dysfunction With Type 2 Diabetes Mellitus Study

Unknown
NCT02567994Phase 3

Tenelia Triple Combination Study

Completed

All 13 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
13